{
    "data": [
        {
            "id": "309720",
            "type": "article",
            "attributes": {
                "publishOn": "2011-11-22T17:07:11-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Pharmasset Acquisition Makes Vertex Look Cheap",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23407",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "95821",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/309720-gileads-pharmasset-acquisition-makes-vertex-look-cheap"
            }
        },
        {
            "id": "309615",
            "type": "article",
            "attributes": {
                "publishOn": "2011-11-22T12:22:39-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Trading Near 52-Week Lows After Gilead Acquires Pharmasset",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24283",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "95813",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/309615-vertex-trading-near-52-week-lows-after-gilead-acquires-pharmasset"
            }
        },
        {
            "id": "303234",
            "type": "article",
            "attributes": {
                "publishOn": "2011-10-28T14:20:46-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Conquers New Markets - It's Time To Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24802",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "95326",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/303234-vertex-conquers-new-markets-its-time-to-buy"
            }
        },
        {
            "id": "303114",
            "type": "article",
            "attributes": {
                "publishOn": "2011-10-28T06:40:07-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex A Steal Based On Blockbuster Hepatitis C Drug Sales",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24414",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "95314",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/303114-vertex-a-steal-based-on-blockbuster-hepatitis-c-drug-sales"
            }
        },
        {
            "id": "295171",
            "type": "article",
            "attributes": {
                "publishOn": "2011-09-21T21:41:10-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Can Vertex Catch Lightning in a Bottle Again?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23407",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "94569",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/295171-can-vertex-catch-lightning-in-a-bottle-again"
            }
        },
        {
            "id": "284109",
            "type": "article",
            "attributes": {
                "publishOn": "2011-08-03T06:33:48-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Does Vertex Pharmaceuticals Deserve a Higher Valuation?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23407",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "93608",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/284109-does-vertex-pharmaceuticals-deserve-a-higher-valuation"
            }
        },
        {
            "id": "274642",
            "type": "article",
            "attributes": {
                "publishOn": "2011-06-13T14:58:37-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: First Drugs Ever to Target Root Cause of Cystic Fibrosis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23183",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "92916",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/274642-vertex-first-drugs-ever-to-target-root-cause-of-cystic-fibrosis"
            }
        },
        {
            "id": "271838",
            "type": "article",
            "attributes": {
                "publishOn": "2011-05-25T14:09:24-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex: The Next Full-Fledged Multinational Pharma?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23183",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/271838-vertex-the-next-full-fledged-multinational-pharma"
            }
        },
        {
            "id": "271581",
            "type": "article",
            "attributes": {
                "publishOn": "2011-05-24T13:21:09-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Pharmaceuticals: A Multi-Billion Dollar Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23407",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "92704",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/271581-vertex-pharmaceuticals-a-multi-billion-dollar-opportunity"
            }
        },
        {
            "id": "263361",
            "type": "article",
            "attributes": {
                "publishOn": "2011-04-13T14:21:15-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Receives Good News on Hepatitis C Treatment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23183",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "92317",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/263361-vertex-receives-good-news-on-hepatitis-c-treatment"
            }
        },
        {
            "id": "256433",
            "type": "article",
            "attributes": {
                "publishOn": "2011-03-04T10:15:26-05:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Vertex Is Not Cheap Medicine",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22561",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "218801",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/256433-vertex-is-not-cheap-medicine"
            }
        },
        {
            "id": "256370",
            "type": "article",
            "attributes": {
                "publishOn": "2011-03-04T02:03:45-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "No Serendipity Involved in Vertex's Achievements",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23183",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "92085",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1102",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/256370-no-serendipity-involved-in-vertexs-achievements"
            }
        }
    ]
}